Tariq Ahmad1, Mona Fiuzat1, Daniel B Mark1, Ben Neely2, Megan Neely2, William E Kraus3, Dalane W Kitzman4, David J Whellan5, Mark Donahue3, Faiez Zannad6, Ileana L Piña7, Kirkwood Adams8, Christopher M O'Connor1, G Michael Felker9. 1. Division of Cardiology, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC. 2. Duke Clinical Research Institute, Durham, NC. 3. Division of Cardiology, Duke University Medical Center, Durham, NC. 4. Wake Forest University, Winston-Salem, NC. 5. Thomas Jefferson University, Philadelphia, PA. 6. Nancy University, Nancy, France. 7. Montefiore Medical Center, Bronx, NY. 8. University of North Carolina, Chapel Hill, NC. 9. Division of Cardiology, Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC. Electronic address: michael.felker@duke.edu.
Abstract
BACKGROUND:Exercise training is recommended for chronic heart failure (HF) patients to improve functional status and reduce risk of adverse outcomes. Elevated plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and cardiac troponin T (cTnT) are associated with increased risk of adverse outcomes in this patient population. Whether exercise training leads to improvements in biomarkers and how such improvements relate to clinical outcomes are unclear. METHODS AND RESULTS: Amino-terminal pro-brain natriuretic peptide, hs-CRP, and cTnT levels were assessed at baseline and 3 months in a cohort of 928 subjects from the HF-ACTION study, a randomized clinical trial of exercise training versus usual care in chronic HF patients with reduced left ventricular ejection fraction (<35%). Linear and logistic regressions were used to assess 3-month biomarker levels as a function of baseline value, treatment assignment (exercise training vs usual care), and volume of exercise. Linear regression and Cox proportional hazard modeling were used to evaluate the relations between changes in biomarker levels and clinical outcomes of interest that included change in peak oxygen consumption (peak VO2), hospitalizations, and mortality. Exercise training was not associated with significant changes in levels of NT-proBNP (P = .10), hs-CRP (P = .80), or detectable cTnT levels (P = .83) at 3 months. Controlling for baseline biomarker levels or volume of exercise did not alter these findings. Decreases in plasma concentrations of NT-proBNP, but not hs-CRP or cTnT, were associated with increases in peak VO2 (P < .001) at 3 months and decreased risk of hospitalizations or mortality (P ≤ .04), even after adjustment for a comprehensive set of known predictors. CONCLUSIONS:Exercise training did not lead to meaningful changes in biomarkers of myocardial stress, inflammation, or necrosis in patients with chronic HF. Only improvements in NT-proBNP translated to reductions in peak VO2 and reduced risk of clinical events.
RCT Entities:
BACKGROUND: Exercise training is recommended for chronic heart failure (HF) patients to improve functional status and reduce risk of adverse outcomes. Elevated plasma levels of amino-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and cardiac troponin T (cTnT) are associated with increased risk of adverse outcomes in this patient population. Whether exercise training leads to improvements in biomarkers and how such improvements relate to clinical outcomes are unclear. METHODS AND RESULTS: Amino-terminal pro-brain natriuretic peptide, hs-CRP, and cTnT levels were assessed at baseline and 3 months in a cohort of 928 subjects from the HF-ACTION study, a randomized clinical trial of exercise training versus usual care in chronic HF patients with reduced left ventricular ejection fraction (<35%). Linear and logistic regressions were used to assess 3-month biomarker levels as a function of baseline value, treatment assignment (exercise training vs usual care), and volume of exercise. Linear regression and Cox proportional hazard modeling were used to evaluate the relations between changes in biomarker levels and clinical outcomes of interest that included change in peak oxygen consumption (peak VO2), hospitalizations, and mortality. Exercise training was not associated with significant changes in levels of NT-proBNP (P = .10), hs-CRP (P = .80), or detectable cTnT levels (P = .83) at 3 months. Controlling for baseline biomarker levels or volume of exercise did not alter these findings. Decreases in plasma concentrations of NT-proBNP, but not hs-CRP or cTnT, were associated with increases in peak VO2 (P < .001) at 3 months and decreased risk of hospitalizations or mortality (P ≤ .04), even after adjustment for a comprehensive set of known predictors. CONCLUSIONS: Exercise training did not lead to meaningful changes in biomarkers of myocardial stress, inflammation, or necrosis in patients with chronic HF. Only improvements in NT-proBNP translated to reductions in peak VO2 and reduced risk of clinical events.
Authors: Christopher M O'Connor; David J Whellan; Daniel Wojdyla; Eric Leifer; Robert M Clare; Stephen J Ellis; Lawrence J Fine; Jerome L Fleg; Faiez Zannad; Steven J Keteyian; Dalane W Kitzman; William E Kraus; David Rendall; Ileana L Piña; Lawton S Cooper; Mona Fiuzat; Kerry L Lee Journal: Circ Heart Fail Date: 2011-11-23 Impact factor: 8.790
Authors: John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher Journal: Eur Heart J Date: 2012-05-19 Impact factor: 29.983
Authors: G Michael Felker; Vic Hasselblad; W H Wilson Tang; Adrian F Hernandez; Paul W Armstrong; Gregg C Fonarow; Adriaan A Voors; Marco Metra; John J V McMurray; Javed Butler; Gretchen M Heizer; Kenneth Dickstein; Barry M Massie; Dan Atar; Richard W Troughton; Stefan D Anker; Robert M Califf; Randall C Starling; Christopher M O'Connor Journal: Eur J Heart Fail Date: 2012-07-04 Impact factor: 15.534
Authors: N A Smart; T Meyer; J A Butterfield; S C Faddy; C Passino; G Malfatto; S Jonsdottir; F Sarullo; U Wisloff; C Vigorito; F Giallauria Journal: Eur J Prev Cardiol Date: 2011-05-04 Impact factor: 7.804
Authors: Steven J Keteyian; Eric S Leifer; Nancy Houston-Miller; William E Kraus; Clinton A Brawner; Christopher M O'Connor; David J Whellan; Lawton S Cooper; Jerome L Fleg; Dalane W Kitzman; Alain Cohen-Solal; James A Blumenthal; David S Rendall; Ileana L Piña Journal: J Am Coll Cardiol Date: 2012-10-10 Impact factor: 24.094
Authors: Christopher R deFilippi; James A de Lemos; Andrew T Tkaczuk; Robert H Christenson; Mercedes R Carnethon; David S Siscovick; John S Gottdiener; Stephen L Seliger Journal: J Am Coll Cardiol Date: 2012-11-14 Impact factor: 24.094
Authors: Tariq Ahmad; Jacob P Kelly; Robert W McGarrah; Anne S Hellkamp; Mona Fiuzat; Jeffrey M Testani; Teresa S Wang; Amanda Verma; Marc D Samsky; Mark P Donahue; Olga R Ilkayeva; Dawn E Bowles; Chetan B Patel; Carmelo A Milano; Joseph G Rogers; G Michael Felker; Christopher M O'Connor; Svati H Shah; William E Kraus Journal: J Am Coll Cardiol Date: 2016-01-26 Impact factor: 24.094
Authors: Laura S Redwine; Meredith A Pung; Kathleen Wilson; Katherine J Bangen; Lisa Delano-Wood; Barry Hurwitz Journal: J Psychosom Res Date: 2019-11-26 Impact factor: 3.006
Authors: Francisco V Santos; Gaspar R Chiappa; Sergio Henrique Rodolpho Ramalho; Alexandra Correa Gervazoni Balbuena de Lima; Fausto Stauffer Junqueira de Souza; Lawrence P Cahalin; João Luiz Quagliotti Durigan; Isac de Castro; Gerson Cipriano Journal: Heart Fail Rev Date: 2018-01 Impact factor: 4.214
Authors: Linda Long; Ify R Mordi; Charlene Bridges; Viral A Sagar; Edward J Davies; Andrew Js Coats; Hasnain Dalal; Karen Rees; Sally J Singh; Rod S Taylor Journal: Cochrane Database Syst Rev Date: 2019-01-29